Cargando...
Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
Gardado en:
| Publicado en: | Clinicoecon Outcomes Res |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6336131/ https://ncbi.nlm.nih.gov/pubmed/30666139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S199650 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|